Atara Biotherapeutics (ATRA) Change in Accured Expenses (2013 - 2026)

Atara Biotherapeutics has reported Change in Accured Expenses for 14 years, with the latest figure at -$166000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 91.66% year-over-year to -$166000.0; the trailing twelve-month figure through Mar 2026 stood at -$3.5 million (up 59.76% YoY), and the FY2025 full-year result was -$5.3 million, up 57.47% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$166000.0, up from -$796000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $14.4 million in Q3 2022, with the low at -$8.8 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$1.3 million across 5 years, with a median of -$2.0 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 277.99% — and 2023, when it slumped 6921.88%.
• Atara Biotherapeutics' Change in Accured Expenses stood at -$3.5 million in 2022, then sank by 91.24% to -$6.7 million in 2023, then soared by 69.5% to -$2.1 million in 2024, then soared by 61.32% to -$796000.0 in 2025, then soared by 79.15% to -$166000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$166000.0 (Q1 2026), -$796000.0 (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.